Global efforts to combat COVID-19 were strengthened by a vaccine developed under the leadership of Nita Patel. In 2022, U.S. regulators authorized the Novavax vaccine, which used a protein-based platform rather than mRNA technology. The achievement demonstrated that established vaccine approaches could be rapidly adapted to emerging pathogens, broadening the world’s pandemic-response toolkit and expanding access to immunization.
